BetterLife Pharma Files 6-K Report

Ticker: BETRF · Form: 6-K · Filed: May 14, 2024 · CIK: 1464165

Sentiment: neutral

Topics: 6-K, foreign-private-issuer, company-update

Related Tickers: BETRF

TL;DR

BetterLife Pharma (BETRF) filed a 6-K, standard foreign issuer report.

AI Summary

BetterLife Pharma Inc. filed a Form 6-K on May 14, 2024, reporting for the month of May 2024. The company, formerly known as Pivot Pharmaceuticals Inc. and Neurokine Pharmaceuticals Inc., is incorporated in A1 and has its principal executive offices in Vancouver, BC. This filing is a report of a foreign private issuer.

Why It Matters

This filing provides routine updates for investors and regulatory bodies regarding BetterLife Pharma Inc.'s status as a foreign private issuer.

Risk Assessment

Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain significant new financial or operational information.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of a foreign private issuer required to be filed with the SEC to provide information that the issuer makes public in its home country, files with a stock exchange, or distributes to its security holders.

What is BetterLife Pharma Inc.'s former company name?

BetterLife Pharma Inc. was formerly known as Pivot Pharmaceuticals Inc. and Neurokine Pharmaceuticals Inc.

Where is BetterLife Pharma Inc. located?

BetterLife Pharma Inc.'s principal executive office is located at 1275 West 6th Avenue, Vancouver, BC V6H 1A6.

What is the SEC file number for BetterLife Pharma Inc.?

The SEC file number for BetterLife Pharma Inc. is 333-161157.

What is the SIC code for BetterLife Pharma Inc.?

The Standard Industrial Classification (SIC) code for BetterLife Pharma Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 356 words · 1 min read · ~1 pages · Grade level 13.5 · Accepted 2024-05-14 16:00:26

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 , the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BETTERLIFE PHARMA INC. Date: May 24, 2024 By: /s/ Moira Ong Name: Moira Ong Title: Chief Financial Officer 3

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing